Eli Lilly Announces Executive Leadership Changes to Propel Future Growth Eli Lilly and Company (NYSE: LLY) today announced a series of executive leadership transitions designed to strengthen its ability to deliver sustained, long-term growth and expand access to its medicines…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) stands as a unique global biopharmaceutical leader, delivering a wide range of medicines to patients around the world. With a legacy spanning over 120 years, Teva has remained steadfast in its mission…
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, today announced its financial results for the first quarter of 2025 and provided a comprehensive business update. CEO Statement…
90% of Adults with Chronic Hepatitis Delta Who Cleared Virus on Bulevirtide Stayed Clear Nearly 2 Years After Stopping Treatment Gilead Sciences, Inc. (Nasdaq: GILD) today announced final results from the Phase 3 MYR301 study showing that nearly 90% of…
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical…
Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab, and pertuzumab (THP), has shown a significantly improved safety profile…
Novo Nordisk Reports Strong Operating Profit and Sales Growth, Updates 2025 Outlook Novo Nordisk announced a 22% increase in operating profit in Danish kroner, or 20% growth at constant exchange rates (CER), reaching DKK 38.8 billion. Sales in the US…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its Elecsys® PRO-C3 test, a new diagnostic tool developed in collaboration with Nordic Bioscience, to assess the severity of liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease…
Teva and Alvotech Expand U.S. Biosimilar Portfolio with Approval for SELARSDI™ Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) have announced that the U.S. Food and Drug Administration (FDA) has…
GSK to Present 43 Abstracts Across Respiratory Portfolio at ATS 2025, Including New Data on Mepolizumab and Depemokimab GSK plc (LSE/NYSE: GSK) today announced that 43 abstracts, including four late-breaking submissions, from its inhaled and respiratory biologics portfolio will be…
AstraZeneca’s Breztri Achieves Primary Endpoints in KALOS and LOGOS Phase III Trials, Marking a Significant Advance in the Treatment of Uncontrolled Asthma AstraZeneca announced encouraging high-level results from its pivotal Phase III KALOS and LOGOS clinical trials evaluating Breztri Aerosphere…
Eli Lilly Reports Strong Q1 2025 Financial Results, Driven by Surging Demand for Mounjaro and Zepbound, While Advancing Pipeline Innovations Eli Lilly and Company (NYSE: LLY) has delivered a robust start to 2025, reporting a 45% year-over-year increase in revenue…